QualityDipStocks / Health Care · Life Sciences Tools
Thermo Fisher Scientific TMO
Outside our quality screen, so we don’t track its dips. It’s 2% below its 52-week high.
Outside our quality screen, trading well above our fair value estimate.
- Fair value est.
- $324.44−53%
- Market Value
- $689.82price +1%
- Off 52-wk high
- −2%
- Risk vs market
- Lowbeta 0.60
3 bullish · 5 bearish See why
Key levels
Every level vs today’s $697.00
- Fair value est.base case$324.44−53.5%
- 52-wk lowlowest close, 1 year$438.34−37.1%
- Market Valueavg paid since Oct 21$689.82−1.0%
- PriceFri Oct 30 close$697.00you are here
- 52-wk highhighest close, 1 year$709.18+1.7%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is above even the bull case.
What the price implies To be worth today’s price, TMO’s free cash flow would need to grow about 17% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much TMO moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 2.3× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.60
- Volatility
- 29% vs 13% SPY
- Correlation SPY
- 0.26
- Correlation QQQ
- 0.14
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
Cash returnsFree cash flow grew 24% over the last 12 months vs the 12 months before.
GrowthSales grew 8% to $47.4B over the last 12 months vs the 12 months before (SEC filings).
Cash returnsShare count down 1.9% over 12 months, below the −1.0% median for the 93 Health Care companies we cover.
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $324.44, 53% below the price.
GrowthSales fell 0.3% a year over the last three fiscal years, below the 7.3% median for the 101 Health Care companies we cover.
ValuationEV/EBITDA of 25.4×, above the 17.0× median for the 55 Health Care companies we cover.
Cash returnsDividend yield of 0.3%, below the 1.1% median for the 47 Health Care companies we cover.
QualityDoesn’t pass our quality screen: net debt 3.1× EBITDA (limit 3×).
Who’s talking about it
Notable investors, executives, analysts and public figures on Thermo Fisher Scientific in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Life Sciences Tools
All fundamentals
P/E 36.6 · FCF yield 2.9% · ROE 13%
Valuation
- P/E
- 36.6×Health Care median 29.2×
- Price / FCF
- 34.0×
- FCF yield
- 2.9%
- EV / EBITDA
- 25.4×
- Price / sales
- 5.46×
- Price / book
- 4.72×
- Market cap
- $259Bprice × diluted shares
- Enterprise value
- $294B
Growth
- Revenue, 12 months
- $47.4B
- Sales growth, 12 months
- +8.3%vs the 12 months before
- Sales growth, 3 yrs
- −0.3%/yrfrom FY2022
- Diluted EPS, 12 months
- $18.96
- EPS growth, last FY
- +7.3%
- Net income, 12 months
- $7.1B
- Net income growth
- +8%12 months vs before
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 17.9%
- Net margin
- 14.9%
- FCF margin
- 16.0%
- Return on equity
- 13%
- Return on invested capital
- 9%
Balance sheet
- Cash & short-term inv.
- $6.1B
- Total debt
- $41.1B
- Net cash
- −$35.0B
- Debt / equity
- 0.75×
- Interest coverage
- 5.5×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $7.6B
- FCF growth, 12 months
- +24%
- Dividend yield
- 0.26%$673M paid
- Payout ratio
- 10%
- Buybacks, 12 months
- $4.0B1.6% of market cap
- Share count, 1 year
- −1.9%diluted shares vs a year ago
- Stock-based comp
- $345M
Trailing 12 months to Sep 26, 2026; balance sheet at Sep 26, 2026. From Thermo Fisher Scientific’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $324.44 · MV $689.82 · FCF value $505.07
Assumes 3.0% growth for 5 years (revenue grew -0.3% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $20.47 a share (trailing 12 months to Sep 26, 2026), from the 10-Q filed Oct 30, 2026. Net debt $35.0B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 59 · 5 days +3.4%
The business
FCF $7.6B · Sales +10%
- Free cash flow, 12 months$7.6B
- Free-cash-flow yield2.9%
- Free-cash-flow margin16%
- Gross margin41%
- Operating margin19%
- Return on invested capital7%
- Return on equity14%
- Sales growth (latest quarter vs year-ago quarter)+10%
- Net debt / EBITDA3.1×
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
TMO is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.